Takeda Pharmaceutical
320 hedge funds and large institutions have $1.2B invested in Takeda Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 136 increasing their positions, 67 reducing their positions, and 33 closing their positions.
12,219% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $216K
111% more capital inflows, than outflows
Capital inflows: $195M | Capital outflows: $92.5M
103% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 67
52% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 33
3% more funds holding
Funds holding: 312 → 320 (+8)
0.24% more ownership
Funds ownership: 2.25% → 2.49% (+0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$42M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$33.5M |
| 3 |
Morgan Stanley
New York
|
+$28.3M |
| 4 |
BlackRock
New York
|
+$13.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.3M |
| 2 |
VanEck Associates
New York
|
-$12.4M |
| 3 |
Goldman Sachs
New York
|
-$12.1M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$9.6M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$6.54M |
TAK Hedge Fund Activity: Q2 2025 in Review
320 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2025, worth a combined $1.2B — up 14% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new TAK positions and 33 closed out — a net gain of 17 holders — while 136 added to existing stakes and 67 trimmed.
The largest buyer was Millennium Management, adding an estimated $42M. The largest seller was Adage Capital Partners, cutting an estimated $13.3M.
- 320 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2025, up from 312 in Q1 2025.
- Funds reported $1.2B of Takeda Pharmaceutical stock for Q2 2025, up 14% quarter-over-quarter.
- 50 funds opened new Takeda Pharmaceutical positions in Q2 2025 and 33 closed out, a net change of +17 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2025 was Millennium Management, an estimated $42M added.
- The largest Takeda Pharmaceutical seller in Q2 2025 was Adage Capital Partners, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2025.